Harvard Bioscience
HBIO
87 hedge funds and large institutions have $82.3M invested in Harvard Bioscience in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 32 increasing their positions, 12 reducing their positions, and 6 closing their positions.
400% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 6
167% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 12
46% more capital invested
Capital invested by funds: $56.4M → $82.3M (+$26M)
36% more funds holding
Funds holding: 64 → 87 (+23)
0.54% more ownership
Funds ownership: 6.38% → 6.92% (+0.54%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.44M |
| 2 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
+$2.73M |
| 3 |
ACM
Archon Capital Management
Seattle,
Washington
|
+$2.2M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.56M |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Engine Capital Management
New York
|
-$10.1M |
| 2 |
HP
Harvey Partners
Tarrytown,
New York
|
-$2.38M |
| 3 |
Millennium Management
New York
|
-$1.31M |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$1.09M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$304K |
HBIO Hedge Fund Activity: Q2 2020 in Review
87 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2020, worth a combined $82.3M — up 46% from $56.4M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new HBIO positions and 6 closed out — a net gain of 24 holders — while 32 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $4.44M. The largest seller was Engine Capital Management, cutting an estimated $10.1M.
- 87 institutional investors held Harvard Bioscience (HBIO) as of Q2 2020, up from 64 in Q1 2020.
- Funds reported $82.3M of Harvard Bioscience stock for Q2 2020, up 46% quarter-over-quarter.
- 30 funds opened new Harvard Bioscience positions in Q2 2020 and 6 closed out, a net change of +24 holders.
- The largest Harvard Bioscience buyer in Q2 2020 was BlackRock, an estimated $4.44M added.
- The largest Harvard Bioscience seller in Q2 2020 was Engine Capital Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2020.